These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 37558851)

  • 61. The prognostic value of controlling nutritional status (CONUT) score-based nomogram on extranodal natural killer/T cell lymphoma patients.
    Zhang S; Sun C; Chen X; Li D; Hu L; Zhang M; Zhang X; Zhang H; Ye J; Wang L; Jia T; Zhu T; Miao Y; Wang C; Wang L; Yan D; Shen Z; Sang W
    Ann Hematol; 2023 Jun; 102(6):1433-1442. PubMed ID: 37074377
    [TBL] [Abstract][Full Text] [Related]  

  • 62. The role of surgical resection in primary central nervous system lymphoma: a single-center retrospective analysis of 70 patients.
    Wu S; Wang J; Liu W; Hu F; Zhao K; Jiang W; Lei T; Shu K
    BMC Neurol; 2021 May; 21(1):190. PubMed ID: 33975554
    [TBL] [Abstract][Full Text] [Related]  

  • 63. A prospective cohort study of methotrexate plus idarubicin in newly diagnosed primary CNS lymphoma.
    Li Q; Ma Y; Lin Z; Ma J; Kang H; Zhang M; Xu H; Chen B
    J Neurooncol; 2023 May; 163(1):39-46. PubMed ID: 35733032
    [TBL] [Abstract][Full Text] [Related]  

  • 64. High-dose chemotherapy and autologous stem cell transplant compared with conventional chemotherapy for consolidation in newly diagnosed primary CNS lymphoma--a randomized phase III trial (MATRix).
    Schorb E; Finke J; Ferreri AJ; Ihorst G; Mikesch K; Kasenda B; Fritsch K; Fricker H; Burger E; Grishina O; Valk E; Zucca E; Illerhaus G
    BMC Cancer; 2016 Apr; 16():282. PubMed ID: 27098429
    [TBL] [Abstract][Full Text] [Related]  

  • 65. [Clinical features and treatment outcomes in primary central nervous system lymphoma: a descriptive analysis of 62 patients].
    Ge Y; Lin XT; Luo DL; Zhang F; Xu J; Li Z; Liu YH
    Zhonghua Bing Li Xue Za Zhi; 2019 Nov; 48(11):861-866. PubMed ID: 31775435
    [No Abstract]   [Full Text] [Related]  

  • 66. Prognostic impact of completion of initial high-dose methotrexate therapy on primary central nervous system lymphoma: a single institution experience.
    Makino K; Nakamura H; Hide T; Kuroda J; Yano S; Kuratsu J
    Int J Clin Oncol; 2015 Feb; 20(1):29-34. PubMed ID: 24722885
    [TBL] [Abstract][Full Text] [Related]  

  • 67. High-dose Methotrexate plus temozolomide with or without rituximab in patients with untreated primary central nervous system lymphoma: A retrospective study from China.
    Chen C; Sun P; Cui J; Yan S; Chen H; Xia Y; Bi X; Liu P; Wang Y; Yang H; Nie M; Zhang XW; Jiang W; Li ZM
    Cancer Med; 2019 Apr; 8(4):1359-1367. PubMed ID: 30821418
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Improved survival with combined chemo-radiotherapy in primary central nervous system lymphoma.
    Abdelsalam M; El-Husseiny G; Akhtar S; Khafaga Y; Al-Shabana M; AlHusaini H; El Weshi A; Rahal M; Maghfoor I
    Hematol Oncol Stem Cell Ther; 2010; 3(3):128-34. PubMed ID: 20890070
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Efficacy and safety of HD-MTX based systemic chemotherapy regimens: retrospective study of induction therapy for primary central nervous system lymphoma in Chinese.
    Han X; Ji Y; Ouyang M; Zhu T; Zhou D
    Sci Rep; 2017 Dec; 7(1):17053. PubMed ID: 29213063
    [TBL] [Abstract][Full Text] [Related]  

  • 70. New genetic prognostic biomarkers in primary central nervous system lymphoma (PCNSL).
    Gomes Candido Reis D; Levy D; Lage LAPC; Culler HF; Rocha V; Bydlowski SP; Nogueira Zerbini MC; Pereira J
    Brain Behav; 2021 Apr; 11(4):e02061. PubMed ID: 33591648
    [TBL] [Abstract][Full Text] [Related]  

  • 71. A retrospective study of 222 patients with newly diagnosed primary central nervous system lymphoma-Outcomes indicative for improved survival overtime.
    Bairey O; Lebel E; Buxbaum C; Porges T; Taliansky A; Gurion R; Goldschmidt N; Shina TT; Zektser M; Hofstetter L; Siegal T
    Hematol Oncol; 2023 Dec; 41(5):838-847. PubMed ID: 37403752
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Outcome of elderly patients with primary CNS lymphoma in the G-PCNSL-SG-1 trial.
    Roth P; Martus P; Kiewe P; Möhle R; Klasen H; Rauch M; Röth A; Kaun S; Thiel E; Korfel A; Weller M
    Neurology; 2012 Aug; 79(9):890-6. PubMed ID: 22895585
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Aberrant methylation in the promoter region of the reduced folate carrier gene is a potential mechanism of resistance to methotrexate in primary central nervous system lymphomas.
    Ferreri AJ; Dell'Oro S; Capello D; Ponzoni M; Iuzzolino P; Rossi D; Pasini F; Ambrosetti A; Orvieto E; Ferrarese F; Arrigoni G; Foppoli M; Reni M; Gaidano G
    Br J Haematol; 2004 Sep; 126(5):657-64. PubMed ID: 15327516
    [TBL] [Abstract][Full Text] [Related]  

  • 74. [Clinical characteristics and prognosis of 49 newly diagnosed primary central nervous system diffuse large B-cell lymphoma].
    Song J; Liu H; Shen HL; Yue LZ; Yang XJ; Song WJ; Sun CY; Yu SZ; Ding K; Wang YH; Li LJ; Yu H; Shao YY; Wang CM; Yue SY; Fu R
    Zhonghua Xue Ye Xue Za Zhi; 2021 Nov; 42(11):917-922. PubMed ID: 35045653
    [No Abstract]   [Full Text] [Related]  

  • 75. Clinical outcomes of newly diagnosed primary CNS lymphoma treated with ibrutinib-based combination therapy: A real-world experience of off-label ibrutinib use.
    Chen F; Pang D; Guo H; Ou Q; Wu X; Jiang X; Wei X; Liu S; Huang L; Liang Z; Zhou D; Li W
    Cancer Med; 2020 Nov; 9(22):8676-8684. PubMed ID: 33068336
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic model.
    Abrey LE; Ben-Porat L; Panageas KS; Yahalom J; Berkey B; Curran W; Schultz C; Leibel S; Nelson D; Mehta M; DeAngelis LM
    J Clin Oncol; 2006 Dec; 24(36):5711-5. PubMed ID: 17116938
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Methotrexate re-challenge for recurrent primary central nervous system lymphoma.
    Pentsova E; Deangelis LM; Omuro A
    J Neurooncol; 2014 Mar; 117(1):161-5. PubMed ID: 24481997
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Advances and challenges in the treatment of primary central nervous system lymphoma.
    Yang H; Xun Y; Yang A; Liu F; You H
    J Cell Physiol; 2020 Dec; 235(12):9143-9165. PubMed ID: 32420657
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Impact of contemporary regimens on the outcomes and toxicity of primary CNS lymphoma: a single-center retrospective analysis of 73 patients.
    Sarid N; Bokstein F; Blumenthal DT; Weiss-Meilik A; Gibstein L; Avivi I; Perry C; Ram R
    J Neurooncol; 2021 Jan; 151(2):211-220. PubMed ID: 33099747
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Long-term outcomes of frontline intensification in primary CNS lymphoma: A real-world single-center experience.
    Wang HY; Yang CF; Lin CH; Hsiao LT; Ko PS; Liu YC; Chiou TJ; Chen PM; Gau JP; Liu JH; Liu CJ
    Cancer Med; 2023 Apr; 12(7):8089-8101. PubMed ID: 36647765
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.